Compare Flagstar Bank NA (FLG) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flagstar Bank NA vs Viatris Inc — how do they compare? Flagstar Bank NA trades at $11.36 (market cap $4.71B), while Viatris Inc trades at $17.49 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 4.3× Flagstar Bank NA's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Flagstar Bank NA for 21 Days and Viatris Inc for 57 Days on average.
| FLG | VTRS | |
|---|---|---|
Market Cap | $4.71B | $20.03B |
Volume | 7,410,589 | 14,109,977 |
Sector | Financials | Health |
52-Week High | $15.36 | $18.27 |
52-Week Low | $10.72 | $9.74 |
Typical Hold Time | 21 Days | 57 Days |
Enterprise Value | $15.25B | $32.15B |
Dividend Yield | 0.35% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Flagstar Bank (FLG) trades at $11.30, down 2.25% on the day, with a bearish technical outlook despite recent earnings beats. The company shows improving fundamentals with Q2 2026 marking the third consecutive profitable quarter, though it missed EPS estimates. Analyst sentiment remains positive with a $17.07 consensus price target representing 51% upside potential. Recent strategic developments include a $250 million share repurchase program and a new core banking partnership with Fiserv.
The stock presents a compelling value opportunity trading at 0.62x book value, but faces risks from volatile earnings performance and negative cash flow trends. While analyst consensus is bullish with 60% buy ratings, investors should monitor execution on profitability improvements and the impact of recent strategic initiatives on long-term growth.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows consistent earnings beats with Q2 2026 EPS of $0.69 exceeding expectations, while maintaining strong operational cash flow of $2.32B in 2025. Recent developments include FDA approval for WAKIX in Japan and continued recognition as a top employer.
Despite negative net margins, Viatris demonstrates improving cash flow trends and strategic portfolio optimization. The stock offers 27% upside to consensus price target of $22.17, though investors face risks from debt levels and competitive pressures in the generic drug market. Deleveraging progress and pipeline advancements support potential re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Flagstar Bank NA
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
